Release Date: 25-Jan-2025
RC108 is an antibody-drug conjugate (ADC) from RemeGen, a Chinese biopharmaceutical enterprise, which targets c-Met, a receptor tyrosine kinase. The activation of c-Met by its ligand, hepatocyte growth factor, initiates several cellular signaling pathways that are crucial for tumor cell proliferation, motility, migration, and invasion. The overexpression or dysregulation of c-Met is linked to unfavorable prognoses in various solid tumors. RC108 is engineered to specifically target c-Met-expressing tumor cells and deliver a cytotoxic payload, potentially hindering tumor growth and metastasis.
Download Insight: https://www.kuickresearch.com/report-cancer-drug-conjugates-market-size
At present, RC108 is in Phase 2 clinical trials in China. These trials aim to assess the safety, efficacy, and potential of RC108 as a standalone treatment for advanced solid tumors that exhibit c-Met expression. Should these trials prove successful, RC108 may offer a targeted therapeutic option for patients with cancers associated with c-Met dysregulation, presenting a promising strategy for managing difficult solid tumors.